News and Announcements

  • Home
  • News and Announcements

Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications

RegenxBIO Announces FDA Clearance Of IND For Clinical Trial Of RGX-202, A Novel Gene Therapy Candidate For Duchenne Muscular Dystrophy

Coherus Announces U.S. FDA Approval of YUSIMRY (adalimumab-aqvh)

Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine

Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Medulloblastoma

Everest Medicines announces FDA grants our Partner Calliditas Therapeutics Accelerated Approval of TARPEYO (budesonide) to Reduce Proteinuria in IgA Nephropathy

Merck Announces Positive Phase III Results for Arpraziquantel as Part of its Schistosomiasis Elimination Program

Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis

BeiGene Announces Acceptance by Swissmedic of Marketing Authorization Application for BRUKINSA (Zanubrutinib) in Waldenstroms Macroglobulinaemia

Novartis secures new approval in China for Cosentyx (secukinumab) in pediatric psoriasis

Positive CHMP opinion for Otsuka's child-friendly 25 mg film-coated tablet formulation Deltyba (Delamanid) for use in pediatric patients weighing 10 kg or more with pulmonary multi-drug-resistant tuberculosis in the EU

Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Disease

Japan becomes the first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19

VALNEVA AND PFIZER COMPLETE RECRUITMENT FOR PHASE II TRIAL OF LYME DISEASE VACCINE CANDIDATE

Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Interim Results from Phase II Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Tezepelumab Regulatory Submission Accepted and Granted FDA Priority Review in the US for the Treatment of Patients with Asthma

DESTINY-Gastric04 Head-to-Head Phase 3 Trial of ENHERTU Initiated in Patients with HER2 Positive Advanced Gastric Cancer

FoundationOne CDx Receives FDA-Approval as a Companion Diagnostic for ALUNBRIG (brigatinib) to Identify Patients with ALK positive Metastatic Non-Small Cell Lung Cancer

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus

Enspryng (satralizumab) from Chugai, approved by the European Commission as the first subcutaneous home treatment for Neuromyelitis Optica Spectrum Disorders (NMOSD)

DARZALEX (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma

BeiGene Announces China NMPA Approval of BRUKINSA (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenstrom Macroglobulinemia

Bayer Submits Regulatory Applications for Oncology Treatment Investigational Combination of Aliqopa (copanlisib) and rituximab in the U.S. and EU

ADC Therapeutics Presents Updated ZYNLONTA (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma

Sciinov Healthcare to announce its new Edition 2023 Conference on LONGEVITY

DENTAL MEET 2023 - Dubai attracts world-renowned Speakers and large international audience

The “Spectacular Progress” In Research Into Slowing Down Aging, Analyzed In Cell By Maria A. Blasco And Other Leading Researchers In The Field

(c) 2021 Sciinov Group - All rights reserved.